| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S9192 R31821 |
Aydin (Phenytoin) (Controls exposed to Lamotrigine, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
13.00 [0.10;1680.94] C excluded (control group) |
0/1 0/7 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9193 R31831 |
Aydin (Phenytoin) (Controls unexposed, sick), 2020 | Small for gestational age (birth weight) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 43.00 [0.35;5328.22] C | 0/1 0/22 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9272 R32151 |
Bank (Phenytoin) (Mixed indications), 2017 | Small for Gestational Age birthweight (<10th percentile) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.86 [0.07;46.97] C | 0/3 3/36 | 3 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9275 R32161 |
Kilic (Phenytoin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.56 [0.28;23.17] C excluded (control group) |
1/5 78/876 | 79 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9276 R32164 |
Kilic (Phenytoin) (Controls unexposed NOS) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: No |
2.34 [0.26;20.91] C excluded (control group) |
1/5 65,118/673,844 | 65,119 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9277 R32167 |
Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.97 [0.22;17.66] C | 1/5 594/5,275 | 595 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9187 R31779 |
Artama (Phenytoin) (Controls exposed to Lamotrigine, sick), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.34 [0.06;28.66] C excluded (control group) |
0/26 2/173 | 2 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9188 R31791 |
Artama (Phenytoin) (Controls unexposed, disease free), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
0.98 [0.06;16.14] C excluded (control group) |
0/26 14,079/719,509 | 14,079 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9190 R31815 |
Artama (Phenytoin) (Controls unexposed, sick), 2013 | Small for gestational age (weight) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.81 [0.05;13.49] C | 0/26 42/1,793 | 42 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9216 R31975 |
Pennell (Phenytoin), 2012 | Small for gestational age (SGA) (at birth) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 0.56 [0.09;3.46] | 2/55 4/98 | 6 | 55 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9223 R31998 |
Wide (Phenytoin), 2000 | Small for gestationnal age | throughout pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 0.86 [0.02;45.54] C | 0/22 0/19 | 0 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.20 [0.40;3.58] | 646 | 112 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Mixed indications; 3: Phenytoin) (Controls unexposed, sick) (Mixed indications; 4: Phenytoin) (Controls unexposed, sick; 5: Phenytoin; 6: Phenytoin;
Asymetry test p-value = 0.1470 (by Egger's regression)
slope=-1.8289 (1.1787); intercept=1.5491 (0.8628); t=1.7955; p=0.1470
excluded 9187, 9188, 9275, 9276, 9192